The DOI matches its Crossref record; 193 of the 193 references it cites were found in a registry or an index.
The Nrf2/HO‐1 Axis in Cancer Cell Growth and Chemoresistance
Open accessAbstract
The transcription factor, nuclear factor erythroid 2 p45‐related factor 2 (Nrf2), acts as a sensor of oxidative or electrophilic stresses and plays a pivotal role in redox homeostasis. Oxidative or electrophilic agents cause a conformational change in the Nrf2 inhibitory protein Keap1 inducing the nuclear translocation of the transcription factor which, through its binding to the antioxidant/electrophilic response element (ARE/EpRE), regulates the expression of antioxidant and detoxifying genes such as heme oxygenase 1 (HO‐1). Nrf2 and HO‐1 are frequently upregulated in different types of tumours and correlate with tumour progression, aggressiveness, resistance to therapy, and poor prognosis. This review focuses on the Nrf2/HO‐1 stress response mechanism as a promising target for anticancer treatment which is able to overcome resistance to therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Nuclear Import and Export Signals in Control of Nrf2
Jain, A. K., Bloom, D. A., & Jaiswal, A. K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502083200 · Cited by 195
RetractedRepertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Itoh, K., Wakabayashi, N., Katoh, Y., Ishii, T., Igarashi, K., Engel, J. D., & Yamamoto, M. (1999) · Genes & Development · doi:10.1101/gad.13.1.76 · Cited by 3,634 · cited 1×
“Thus, Keap1 is the main repressor of Nrf2, having three functional domains, namely, the broad complex, Tramtrack, and Bric-a-Brac (BTB) domain, the intervening region (IVR) domain, and the double glycine repeat (DGR)/Kelch domain [25] (Figure 1(b)).”
BackgroundBilirubin Is an Antioxidant of Possible Physiological Importance
Stocker, R., Yamamoto, Y., McDonagh, A. F., Glazer, A. N., & Ames, B. N. (1987) · Science · doi:10.1126/science.3029864 · Cited by 2,948
Komatsu, M., Kurokawa, H., Waguri, S., Taguchi, K., Kobayashi, A., Ichimura, Y., Sou, Y.-S., Ueno, I., Sakamoto, A., Tong, K. I., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2021 · Cited by 2,288
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Kobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224
The Nrf2 regulatory network provides an interface between redox and intermediary metabolism
Hayes, J. D., & Dinkova-Kostova, A. T. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.02.002 · Cited by 2,141
Dinkova-Kostova, A. T., Holtzclaw, W. D., Cole, R. N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., & Talalay, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398899 · Cited by 1,947
Heme oxygenase: Function, multiplicity, regulatory mechanisms, and clinical applications
Maines, M. D. (1988) · The FASEB Journal · doi:10.1096/fasebj.2.10.3290025 · Cited by 1,707
Moi, P., Chan, K., Asunis, I., Cao, A., & Kan, Y. W. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9926 · Cited by 1,607
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
Taguchi, K., Motohashi, H., & Yamamoto, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01473.x · Cited by 1,478
Jain, A., Lamark, T., Sjøttem, E., Bowitz Larsen, K., Atesoh Awuh, J., Øvervatn, A., McMahon, M., Hayes, J. D., & Johansen, T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.118976 · Cited by 1,472
Ishii, T., Itoh, K., Takahashi, S., Sato, H., Yanagawa, T., Katoh, Y., Bannai, S., & Yamamoto, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.21.16023 · Cited by 1,460
The emerging role of the Nrf2–Keap1 signaling pathway in cancer
Jaramillo, M. C., & Zhang, D. D. (2013) · Genes & Development · doi:10.1101/gad.225680.113 · Cited by 1,297
Keyse, S. M., & Tyrrell, R. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.1.99 · Cited by 1,264
Role of Glutathione in Cancer Progression and Chemoresistance
Traverso, N., Ricciarelli, R., Nitti, M., Marengo, B., Furfaro, A. L., Pronzato, M. A., Marinari, U. M., & Domenicotti, C. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/972913 · Cited by 1,208
Self-citationPhosphorylation of p62 Activates the Keap1-Nrf2 Pathway during Selective Autophagy
Ichimura, Y., Waguri, S., Sou, Y.-S., Kageyama, S., Hasegawa, J., Ishimura, R., Saito, T., Yang, Y., Kouno, T., Fukutomi, T., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.08.003 · Cited by 1,205
Ramos-Gomez, M., Kwak, M.-K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., & Kensler, T. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051618798 · Cited by 1,102
Mechanistic Studies of the Nrf2-Keap1 Signaling Pathway
Zhang, D. D. (2006) · Drug Metabolism Reviews · doi:10.1080/03602530600971974 · Cited by 1,086
The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation
Bryan, H. K., Olayanju, A., Goldring, C. E., & Park, B. K. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.016 · Cited by 1,024
Wakabayashi, N., Dinkova-Kostova, A. T., Holtzclaw, W. D., Kang, M.-I., Kobayashi, A., Yamamoto, M., Kensler, T. W., & Talalay, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307301101 · Cited by 986 · cited 1×
“Themain three cysteine residues for the regulation of Nrf2 activity are Cys151 in the BTB domain and Cys273 and Cys288 in the IVR domain, all of which are targets of oxidative and electrophilic modifications [27–29].”
BackgroundCullinan, S. B., Gordan, J. D., Jin, J., Harper, J. W., & Diehl, J. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8477-8486.2004 · Cited by 986
Carbon Monoxide Generated by Heme Oxygenase 1 Suppresses Endothelial Cell Apoptosis
Brouard, S., Otterbein, L. E., Anrather, J., Tobiasch, E., Bach, F. H., Choi, A. M. K., & Soares, M. P. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1015 · Cited by 984
Kobayashi, A., Kang, M.-I., Watai, Y., Tong, K. I., Shibata, T., Uchida, K., & Yamamoto, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.1.221-229.2006 · Cited by 933
NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer
Hayes, J. D., & McMahon, M. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2008.12.008 · Cited by 869
DJ‐1 has a role in antioxidative stress to prevent cell death
Taira, T., Saito, Y., Niki, T., Iguchi‐Ariga, S. M. M., Takahashi, K., & Ariga, H. (2004) · EMBO reports · doi:10.1038/sj.embor.7400074 · Cited by 853
Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2
Wang, X.-J., Sun, Z., Villeneuve, N. F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G. T., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn095 · Cited by 839
Clements, C. M., McNally, R. S., Conti, B. J., Mak, T. W., & Ting, J. P.-Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607260103 · Cited by 818
Malhotra, D., Portales-Casamar, E., Singh, A., Srivastava, S., Arenillas, D., Happel, C., Shyr, C., Wakabayashi, N., Kensler, T. W., Wasserman, W. W., et al. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq212 · Cited by 794
Small Molecule Modulators of Keap1‐ Nrf2‐ ARE Pathway as Potential Preventive and Therapeutic Agents
Magesh, S., Chen, Y., & Hu, L. (2012) · Medicinal Research Reviews · doi:10.1002/med.21257 · Cited by 760 · cited 1×
“Furthermore, all-trans-retinoic acid (ATRA) is able to suppress the Nrf2 pathway [184].”
BackgroundTong, K. I., Katoh, Y., Kusunoki, H., Itoh, K., Tanaka, T., & Yamamoto, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.2887-2900.2006 · Cited by 759
Rada, P., Rojo, A. I., Chowdhry, S., McMahon, M., Hayes, J. D., & Cuadrado, A. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01204-10 · Cited by 759 · cited 3×
“The Neh6 domainmediates the Keap1-independent degradation ofNrf2 through recruitment by the DSGIS and DSAPGS motifs of the dimericβ-transducin repeat-containing protein (β-TrCP) [19].”
BackgroundMaines, M. D., Trakshel, G. M., & Kutty, R. K. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42488-4 · Cited by 759
Gupta, S. C., Hevia, D., Patchva, S., Park, B., Koh, W., & Aggarwal, B. B. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4414 · Cited by 732
Shibata, T., Ohta, T., Tong, K. I., Kokubu, A., Odogawa, R., Tsuta, K., Asamura, H., Yamamoto, M., & Hirohashi, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806268105 · Cited by 728
Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism
Ren, D., Villeneuve, N. F., Jiang, T., Wu, T., Lau, A., Toppin, H. A., & Zhang, D. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014275108 · Cited by 673
Chowdhry, S., Zhang, Y., McMahon, M., Sutherland, C., Cuadrado, A., & Hayes, J. D. (2013) · Oncogene · doi:10.1038/onc.2012.388 · Cited by 657
LAU, A., VILLENEUVE, N., SUN, Z., WONG, P., & ZHANG, D. (2008) · Pharmacological Research · doi:10.1016/j.phrs.2008.09.003 · Cited by 645
Direct Interaction between Nrf2 and p21Cip1/WAF1 Upregulates the Nrf2-Mediated Antioxidant Response
Chen, W., Sun, Z., Wang, X.-J., Jiang, T., Huang, Z., Fang, D., & Zhang, D. D. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.04.029 · Cited by 638
Kobayashi, M., Li, L., Iwamoto, N., Nakajima-Takagi, Y., Kaneko, H., Nakayama, Y., Eguchi, M., Wada, Y., Kumagai, Y., & Yamamoto, M. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01080-08 · Cited by 638
Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha
Chorley, B. N., Campbell, M. R., Wang, X., Karaca, M., Sambandan, D., Bangura, F., Xue, P., Pi, J., Kleeberger, S. R., & Bell, D. A. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks409 · Cited by 558
Nrf2 signaling: An adaptive response pathway for protection against environmental toxic insults
OSBURN, W., & KENSLER, T. (2008) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2007.11.006 · Cited by 549
Nrf2 as a novel molecular target for chemoprevention
Lee, J.-S., & Surh, Y.-J. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.09.042 · Cited by 516
Physiological Significance of Reactive Cysteine Residues of Keap1 in Determining Nrf2 Activity
Yamamoto, T., Suzuki, T., Kobayashi, A., Wakabayashi, J., Maher, J., Motohashi, H., & Yamamoto, M. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01704-07 · Cited by 513
Discovery of the Negative Regulator of Nrf2, Keap1: A Historical Overview
Itoh, K., Mimura, J., & Yamamoto, M. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3222 · Cited by 510
Keap1 degradation by autophagy for the maintenance of redox homeostasis
Taguchi, K., Fujikawa, N., Komatsu, M., Ishii, T., Unno, M., Akaike, T., Motohashi, H., & Yamamoto, M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121572109 · Cited by 482
CHANAS, S. A., JIANG, Q., McMAHON, M., McWALTER, G. K., McLELLAN, L. I., ELCOMBE, C. R., HENDERSON, C. J., WOLF, C. R., MOFFAT, G. J., ITOH, K., et al. (2002) · Biochemical Journal · doi:10.1042/bj20020320 · Cited by 460
Nrf2–MafG heterodimers contribute globally to antioxidant and metabolic networks
Hirotsu, Y., Katsuoka, F., Funayama, R., Nagashima, T., Nishida, Y., Nakayama, K., Douglas Engel, J., & Yamamoto, M. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks827 · Cited by 431
Nrf2 Enhances Cell Proliferation and Resistance to Anticancer Drugs in Human Lung Cancer
Homma, S., Ishii, Y., Morishima, Y., Yamadori, T., Matsuno, Y., Haraguchi, N., Kikuchi, N., Satoh, H., Sakamoto, T., Hizawa, N., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2822 · Cited by 418
Lavrovsky, Y., Schwartzman, M. L., Levere, R. D., Kappas, A., & Abraham, N. G. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.13.5987 · Cited by 403
Ishii, T., Itoh, K., Ruiz, E., Leake, D. S., Unoki, H., Yamamoto, M., & Mann, G. E. (2004) · Circulation Research · doi:10.1161/01.res.0000119171.44657.45 · Cited by 398
The Keap1–Nrf2 system in cancers: stress response and anabolic metabolism
Mitsuishi, Y., Motohashi, H., & Yamamoto, M. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00200 · Cited by 392
Heme Oxygenase-1 in Tumors: Is It a False Friend?
Jozkowicz, A., Was, H., & Dulak, J. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1659 · Cited by 382
Wang, H., Liu, K., Geng, M., Gao, P., Wu, X., Hai, Y., Li, Y., Li, Y., Luo, L., Hayes, J. D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3386 · Cited by 382
Xu, C., Huang, M.-T., Shen, G., Yuan, X., Lin, W., Khor, T. O., Conney, A. H., & Kong, A.-N. T. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0300 · Cited by 380
Zhang, P., Singh, A., Yegnasubramanian, S., Esopi, D., Kombairaju, P., Bodas, M., Wu, H., Bova, S. G., & Biswal, S. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0589 · Cited by 374
Iida, K., Itoh, K., Kumagai, Y., Oyasu, R., Hattori, K., Kawai, K., Shimazui, T., Akaza, H., & Yamamoto, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1906 · Cited by 370
Nrf2: A Potential Molecular Target for Cancer Chemoprevention by Natural Compounds
Jeong, W.-S., Jun, M., & Kong, A.-N. T. (2006) · Antioxidants & Redox Signaling · doi:10.1089/ars.2006.8.99 · Cited by 367
Targeting heme oxygenase-1 and carbon monoxide for therapeutic modulation of inflammation
Ryter, S. W., & Choi, A. M. K. (2016) · Translational Research · doi:10.1016/j.trsl.2015.06.011 · Cited by 362
Hrd1 suppresses Nrf2-mediated cellular protection during liver cirrhosis
Wu, T., Zhao, F., Gao, B., Tan, C., Yagishita, N., Nakajima, T., Wong, P. K., Chapman, E., Fang, D., & Zhang, D. D. (2014) · Genes & Development · doi:10.1101/gad.238246.114 · Cited by 353
Natural product-derived pharmacological modulators of Nrf2/ARE pathway for chronic diseases
Kumar, H., Kim, I.-S., More, S. V., Kim, B.-W., & Choi, D.-K. (2014) · Nat. Prod. Rep. · doi:10.1039/c3np70065h · Cited by 333
Tang, X., Wang, H., Fan, L., Wu, X., Xin, A., Ren, H., & Wang, X. J. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.03.008 · Cited by 325
Kensler, T. W., Chen, J.-G., Egner, P. A., Fahey, J. W., Jacobson, L. P., Stephenson, K. K., Ye, L., Coady, J. L., Wang, J.-B., Wu, Y., et al. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0368 · Cited by 317
Maher, J. M., Dieter, M. Z., Aleksunes, L. M., Slitt, A. L., Guo, G., Tanaka, Y., Scheffer, G. L., Chan, J. Y., Manautou, J. E., Chen, Y., et al. (2007) · Hepatology · doi:10.1002/hep.21831 · Cited by 315
Wang, X. J., Hayes, J. D., Henderson, C. J., & Wolf, C. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709483104 · Cited by 309
Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer
Khor, T. O., Huang, M.-T., Prawan, A., Liu, Y., Hao, X., Yu, S., Cheung, W. K. L., Chan, J. Y., Reddy, B. S., Yang, C. S., et al. (2008) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0028 · Cited by 306
Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer
Sadeghi, N., Abbruzzese, J. L., Yeung, S.-C. J., Hassan, M., & Li, D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2994 · Cited by 305
MacLeod, A. K., McMahon, M., Plummer, S. M., Higgins, L. G., Penning, T. M., Igarashi, K., & Hayes, J. D. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp176 · Cited by 297
Foresti, R., Clark, J. E., Green, C. J., & Motterlini, R. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.29.18411 · Cited by 294
NRF2 Blockade Suppresses Colon Tumor Angiogenesis by Inhibiting Hypoxia-Induced Activation of HIF-1α
Kim, T.-H., Hur, E.-G., Kang, S.-J., Kim, J.-A., Thapa, D., Lee, Y. M., Ku, S. K., Jung, Y., & Kwak, M.-K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3007 · Cited by 292
Oncogenic KRAS Confers Chemoresistance by Upregulating NRF2
Tao, S., Wang, S., Moghaddam, S. J., Ooi, A., Chapman, E., Wong, P. K., & Zhang, D. D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1439 · Cited by 291
High Levels of Nrf2 Determine Chemoresistance in Type II Endometrial Cancer
Jiang, T., Chen, N., Zhao, F., Wang, X.-J., Kong, B., Zheng, W., & Zhang, D. D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0713 · Cited by 286 · cited 1×
“Indeed, the stable overexpression of Nrf2 was found in various types of tumours such as lung [49, 50], breast [51], head and neck [52], ovarian [53], and endometrial cancer [54].”
BackgroundValidation of the multiple sensor mechanism of the Keap1-Nrf2 system
Takaya, K., Suzuki, T., Motohashi, H., Onodera, K., Satomi, S., Kensler, T. W., & Yamamoto, M. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.06.023 · Cited by 276
Reactive oxygen species-dependent signaling regulates cancer
Weinberg, F., & Chandel, N. S. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0099-y · Cited by 275
Yates, M. S., Tran, Q. T., Dolan, P. M., Osburn, W. O., Shin, S., McCulloch, C. C., Silkworth, J. B., Taguchi, K., Yamamoto, M., Williams, C. R., et al. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp100 · Cited by 269
Heme Oxygenase-1 and the Vascular Bed: From Molecular Mechanisms to Therapeutic Opportunities
Loboda, A., Jazwa, A., Grochot-Przeczek, A., Rutkowski, A. J., Cisowski, J., Agarwal, A., Jozkowicz, A., & Dulak, J. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2043 · Cited by 265
Berberat, P. O., Dambrauskas, Z., Gulbinas, A., Giese, T., Giese, N., Künzli, B., Autschbach, F., Meuer, S., Büchler, M. W., & Friess, H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2159 · Cited by 263
Copple, I. M., Lister, A., Obeng, A. D., Kitteringham, N. R., Jenkins, R. E., Layfield, R., Foster, B. J., Goldring, C. E., & Park, B. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.096545 · Cited by 260
Heme oxygenase-1 in tumor biology and therapy
Was, H., Dulak, J., & Jozkowicz, A. (2010) · Current Drug Targets · doi:10.2174/1389450111009011551 · Cited by 259
Hast, B. E., Goldfarb, D., Mulvaney, K. M., Hast, M. A., Siesser, P. F., Yan, F., Hayes, D. N., & Major, M. B. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4400 · Cited by 259
Agyeman, A. S., Chaerkady, R., Shaw, P. G., Davidson, N. E., Visvanathan, K., Pandey, A., & Kensler, T. W. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1536-9 · Cited by 251
Heme Oxygenase-1: Redox Regulation of a Stress Protein in Lung and Cell Culture Models
Ryter, S. W., & Choi, A. M. K. (2005) · Antioxidants & Redox Signaling · doi:10.1089/ars.2005.7.80 · Cited by 243
Conaway, C. C., Wang, C.-X., Pittman, B., Yang, Y.-M., Schwartz, J. E., Tian, D., McIntee, E. J., Hecht, S. S., & Chung, F.-L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0237 · Cited by 240
Intratumoral hypoxia, radiation resistance, and HIF-1
Semenza, G. L. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00118-7 · Cited by 235
Olayanju, A., Copple, I. M., Bryan, H. K., Edge, G. T., Sison, R. L., Wong, M. W., Lai, Z.-Q., Lin, Z.-X., Dunn, K., Sanderson, C. M., et al. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.11.003 · Cited by 232
Transcriptional Activation of the Heme Oxygenase Gene by Heme and Cadmium in Mouse Hepatoma Cells
Alam, J., Shibahara, S., & Smith, A. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)83358-0 · Cited by 226
Roles of Nrf2 in cell proliferation and differentiation
Murakami, S., & Motohashi, H. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.030 · Cited by 225
Regulation of Notch1 Signaling by Nrf2: Implications for Tissue Regeneration
Wakabayashi, N., Shin, S., Slocum, S. L., Agoston, E. S., Wakabayashi, J., Kwak, M.-K., Misra, V., Biswal, S., Yamamoto, M., & Kensler, T. W. (2010) · Science Signaling · doi:10.1126/scisignal.2000762 · Cited by 224
Fang, J. Q., Sawa, T., Akaike, T., Akuta, T., Sahoo, S. K., Greish, K. F., Hamada, A., & Maeda, H. (2003) · PubMed · Cited by 223
Nrf2: control of sensitivity to carcinogens
Slocum, S. L., & Kensler, T. W. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0675-4 · Cited by 219
Heme oxygenase-1 accelerates tumor angiogenesis of human pancreatic cancer
Sunamura, M., Duda, D. G., Ghattas, M. H., Lozonschi, L., Motoi, F., Yamauchi, J.-I., Matsuno, S., Shibahara, S., & Abraham, N. G. (2003) · Angiogenesis · doi:10.1023/a:1025803600840 · Cited by 215
Heme Oxygenase-1 as a Potential Therapeutic Target for Hepatoprotection
Farombi, E. O., & Surh, Y.-J. (2006) · BMB Reports · doi:10.5483/bmbrep.2006.39.5.479 · Cited by 215
A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity
Nioi, P., & Nguyen, T. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.08.051 · Cited by 212
Nrf2 regulates haematopoietic stem cell function
Tsai, J. J., Dudakov, J. A., Takahashi, K., Shieh, J.-H., Velardi, E., Holland, A. M., Singer, N. V., West, M. L., Smith, O. M., Young, L. F., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2699 · Cited by 202
Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1
Na, H.-K., & Surh, Y.-J. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.10.819 · Cited by 202
Molecular Basis of Heme Oxygenase-1 Induction: Implications for Chemoprevention and Chemoprotection
Prawan, A., Kundu, J. K., & Surh, Y.-J. (2005) · Antioxidants & Redox Signaling · doi:10.1089/ars.2005.7.1688 · Cited by 195
Overexpression of Heme Oxygenase-1 in Murine Melanoma
Was, H., Cichon, T., Smolarczyk, R., Rudnicka, D., Stopa, M., Chevalier, C., Leger, J. J., Lackowska, B., Grochot, A., Bojkowska, K., et al. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.051365 · Cited by 192
PALB2 Interacts with KEAP1 To Promote NRF2 Nuclear Accumulation and Function
Ma, J., Cai, H., Wu, T., Sobhian, B., Huo, Y., Alcivar, A., Mehta, M., Cheung, K. L., Ganesan, S., Kong, A.-N. T., et al. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06271-11 · Cited by 192
Singh, A., Wu, H., Zhang, P., Happel, C., Ma, J., & Biswal, S. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0108 · Cited by 192
Methylation of the KEAP1 gene promoter region in human colorectal cancer
Hanada, N., Takahata, T., Zhou, Q., Ye, X., Sun, R., Itoh, J., Ishiguro, A., Kijima, H., Mimura, J., Itoh, K., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-66 · Cited by 190
Hu, R., Saw, C. L.-L., Yu, R., & Kong, A.-N. T. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3276 · Cited by 187
The transcription factor NF‐E2‐related Factor 2 (Nrf2): a protooncogene?
Shelton, P., & Jaiswal, A. K. (2013) · The FASEB Journal · doi:10.1096/fj.12-217257 · Cited by 186
Garg, R., Gupta, S., & Maru, G. B. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn064 · Cited by 185
Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity
Nowis, D., Legat, M., Grzela, T., Niderla, J., Wilczek, E., Wilczynski, G. M., Głodkowska, E., Mrówka, P., Issat, T., Dulak, J., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209378 · Cited by 184
Terry, C. M., Clikeman, J. A., Hoidal, J. R., & Callahan, K. S. (1998) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1998.274.3.h883 · Cited by 182
Mitochondrial SKN-1/Nrf Mediates a Conserved Starvation Response
Paek, J., Lo, J. Y., Narasimhan, S. D., Nguyen, T. N., Glover-Cutter, K., Robida-Stubbs, S., Suzuki, T., Yamamoto, M., Blackwell, T. K., & Curran, S. P. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.09.007 · Cited by 181
Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo
Chian, S., Thapa, R., Chi, Z., Wang, X. J., & Tang, X. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.04.039 · Cited by 166
Heme Oxygenase-1: A Metabolic Nike
Wegiel, B., Nemeth, Z., Correa-Costa, M., Bulmer, A. C., & Otterbein, L. E. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5667 · Cited by 166
Dual roles of NRF2 in tumor prevention and progression: Possible implications in cancer treatment
Moon, E. J., & Giaccia, A. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.11.009 · Cited by 160
Ooi, A., Dykema, K., Ansari, A., Petillo, D., Snider, J., Kahnoski, R., Anema, J., Craig, D., Carpten, J., Teh, B.-T., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3227 · Cited by 159
Singh, B., Shoulson, R. L., Chatterjee, A., Ronghe, A. M., Bhat, N. K., Dim, D. C., & Bhat, H. K. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu120 · Cited by 159
Hill, M., Pereira, V., Chauveau, C., Zagani, R., Remy, S., Tesson, L., Mazal, D., Ubillos, L., Brion, R., Ashgar, K., et al. (2005) · The FASEB Journal · doi:10.1096/fj.05-3875com · Cited by 158
Mayerhofer, M., Florian, S., Krauth, M., Aichberger, K. J., Bilban, M., Marculescu, R., Printz, D., Fritsch, G., Wagner, O. F., Selzer, E., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1200 · Cited by 154
MacKeigan, J. P., Clements, C. M., Lich, J. D., Pope, R. M., Hod, Y., & Ting, J. P. ‐. (2003) · PubMed · Cited by 152
Stacy, D., Ely, K., Massion, P. P., Yarbrough, W. G., Hallahan, D. E., Sekhar, K. R., & Freeman, M. L. (2006) · Head & Neck · doi:10.1002/hed.20430 · Cited by 141
Identification of polymorphisms in the promoter region of the human NRF2 gene
Yamamoto, T., Yoh, K., Kobayashi, A., Ishii, Y., Kure, S., Kôyama, A., Sakamoto, T., Sekizawa, K., Motohashi, H., & Yamamoto, M. P. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.06.112 · Cited by 140
Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer
Muscarella, L. A., Parrella, P., D’Alessandro, V., la Torre, A., Barbano, R., Fontana, A., Tancredi, A., Guarnieri, V., Balsamo, T., Coco, M., et al. (2011) · Epigenetics · doi:10.4161/epi.6.6.15773 · Cited by 139
Sahoo, S. K., Sawa, T., Fang, J. Q., Tanaka, S., Miyamoto, Y., Akaike, T., & Maeda, H. (2002) · Bioconjugate Chemistry · doi:10.1021/bc020010k · Cited by 138
A Novel Experimental Heme Oxygenase-1–Targeted Therapy for Hormone-Refractory Prostate Cancer
Alaoui‐Jamali, M. A., Bismar, T. A., Gupta, A., Szarek, W. A., Su, J., Song, W., Xu, Y., Xu, B., Liu, G., Vlahakis, J. Z., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0419 · Cited by 138
DNA repair and cancer stem-like cells – Potential partners in glioma drug resistance?
Johannessen, T.-C. A., Bjerkvig, R., & Tysnes, B. B. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2008.03.125 · Cited by 135
Shibata, T., Saito, S., Kokubu, A., Suzuki, T., Yamamoto, M. P., & Hirohashi, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0384 · Cited by 135
Jayakumar, S., Kunwar, A., Sandur, S. K., Pandey, B. N., & Chaubey, R. C. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.10.006 · Cited by 133
Lee, S., Lim, M., Kim, M., Yu, C., Yun, Y., Ahn, J., & Song, J. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.05.038 · Cited by 133
Shim, G.-S., Manandhar, S., Shin, D., Kim, T., & Kwak, M. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.09.006 · Cited by 131
Camp, N. D., James, R. G., Dawson, D. W., Yan, F., Davison, J. M., Houck, S. A., Tang, X., Zheng, N., Major, M. B., & Moon, R. T. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.316471 · Cited by 131
Chemoprotection by Organosulfur Inducers of Phase 2 Enzymes: Dithiolethiones and Dithiins
Kensler, T. W., Curphey, T. J., Maxiutenko, Y., & Roebuck, B. D. (2000) · Drug metabolism and drug interactions · doi:10.1515/dmdi.2000.17.1-4.3 · Cited by 131
Regulatory Nexus of Synthesis and Degradation Deciphers Cellular Nrf2 Expression Levels
Suzuki, T., Shibata, T., Takaya, K., Shiraishi, K., Kohno, T., Kunitoh, H., Tsuta, K., Furuta, K., Goto, K., Hosoda, F., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00065-13 · Cited by 128
Truong, M., Kim, H. G., Khanal, T., Choi, J. H., Kim, D. H., Jeong, T. C., & Jeong, H. G. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.05.010 · Cited by 127
Iyer, A. K., Greish, K. F., Seki, T., Okazaki, S., Fang, J. Q., Takeshita, K., & Maeda, H. (2007) · Journal of drug targeting · doi:10.1080/10611860701498252 · Cited by 126
Nrf2 is required to maintain the self-renewal of glioma stem cells
Zhu, J., Wang, H., Sun, Q., Ji, X., Zhu, L., Cong, Z., Zhou, Y., Liu, H., & Zhou, M. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-380 · Cited by 122
Multiplicity of Heme Oxygenase Isozymes
Trakshel, G. M., & Maines, M. D. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85089-5 · Cited by 121
Oxidative stress, mammospheres and Nrf2–new implication for breast cancer therapy?
Wu, T., Harder, B. G., Wong, P. K., Lang, J. E., & Zhang, D. D. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22202 · Cited by 121
Keap1‐Nrf2 activation in the presence and absence of DJ‐1
Gan, L., Johnson, D. A., & Johnson, J. A. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07138.x · Cited by 119
Nrf2–ARE signaling pathway and natural products for cancer chemoprevention
Zhao, C. R., Gao, Z. H., & Qu, X. J. (2010) · Cancer Epidemiology · doi:10.1016/j.canep.2010.06.012 · Cited by 116
Chemistry of the Cysteine Sensors in Kelch-Like ECH-Associated Protein 1
Holland, R., & Fishbein, J. C. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3273 · Cited by 115
Chian, S., Li, Y., Wang, X. J., & Tang, X. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.6.2911 · Cited by 114
Identification of aldo-keto reductases as NRF2-target marker genes in human cells
Jung, K.-A., Choi, B.-H., Nam, C.-W., Song, M., Kim, S.-T., Lee, J. Y., & Kwak, M.-K. (2013) · Toxicology Letters · doi:10.1016/j.toxlet.2012.12.026 · Cited by 113
Zhong, Y., Zhang, F., Sun, Z., Zhou, W., Li, Z., You, Q., Guo, Q., & Hu, R. (2012) · Molecular Carcinogenesis · doi:10.1002/mc.21921 · Cited by 112
Heme oxygenase-1 and its metabolites affect pancreatic tumor growth in vivo
Nuhn, P., Künzli, B. M., Hennig, R., Mitkus, T., Ramanauskas, T., Nobiling, R., Meuer, S. C., Frieß, H., & Berberat, P. O. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-37 · Cited by 112
Kim, J.-H., Yu, S., Chen, J. D., & Kong, A.-N. T. (2012) · Oncogene · doi:10.1038/onc.2012.59 · Cited by 111
Tsai, J., Wang, H., Liu, P., Chen, Y., Yang, M.-C., Chou, S., Cheng, Y.-J., Yin, W. H., Hwang, J.-J., & Chong, I. (2012) · Cellular Oncology · doi:10.1007/s13402-012-0105-5 · Cited by 110
Wang, L., Li, Y., Sn, Y., Wang, F.-Y., Hou, Y., Cui, W., Chen, K., Cao, Q., Wang, S., Ty, Z., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.752 · Cited by 110
Nrf2 and p21 regulate the fine balance between life and death by controlling ROS levels
Villeneuve, N. F., Sun, Z., Chen, W., & Zhang, D. D. (2009) · Cell Cycle · doi:10.4161/cc.8.20.9565 · Cited by 107
Yin, H., Fang, J. Q., Liao, L., Maeda, H., & Su, Q. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-436 · Cited by 105
Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma.
Bao, L.-J., Jaramillo, M. C., Zhang, Z.-B., Zheng, Y.-X., Yao, M., Zhang, D. D., & Yi, X.-F. (2014) · Europe PMC (PubMed Central) · Cited by 103
Sass, G., Leukel, P., Schmitz, V., Raskopf, E., Ocker, M., Neureiter, D., Meissnitzer, M. W., Tasika, E., Tannapfel, A., & Tiegs, G. (2008) · International Journal of Cancer · doi:10.1002/ijc.23695 · Cited by 100
Loignon, M., Miao, W., Hu, L., Bier, A., Bismar, T. A., Scrivens, P. J., Mann, K. K., Basik, M., Bouchard, A., Fiset, P., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1186 · Cited by 100
Heme oxygenase-1 inhibits apoptosis in Caco-2 cells via activation of Akt pathway
Busserolles, J., Megías, J., Terencio, M. C., & Alcaraz, M. J. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2006.03.013 · Cited by 99
Degese, M. S., Mendizabal, J., Gandini, N. A., Gutkind, J. S., Molinolo, A. A., Hewitt, S. M., Curino, A. C., Coso, O. A., & Facchinetti, M. M. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.02.016 · Cited by 97
Cytoprotection “gone astray’’: Nrf2 and its role in cancer
Schäfer, H., Geismann, C., Arlt, A., & Sebens, S. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s36624 · Cited by 93
You, A., Nam, C.-W., Wakabayashi, N., Yamamoto, M. P., Kensler, T. W., & Kwak, M.-K. (2011) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2010.12.034 · Cited by 88
Łoboda, A., Jaźwa, A., Wegiel, B., Józkowicz, A., & Dulak, J. (2005) · PubMed · Cited by 85
Heme oxygenase 1 (HO-1) challenges the angiogenic switch in prostate cancer
Ferrando, M., Gueron, G., Elguero, B., Giudice, J., Salles, A., Leskow, F. C., Jares-Erijman, E. A., Colombo, L. L., Meiss, R. P., Navone, N. M., et al. (2011) · Angiogenesis · doi:10.1007/s10456-011-9230-4 · Cited by 81
Marinissen, M. J., Tanos, T., Bolós, M., de Sagarra, M. R., Coso, O. A., & Cuadrado, A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512199200 · Cited by 78
Retinoic acid synergizes ATO-mediated cytotoxicity by precluding Nrf2 activity in AML cells
Valenzuela, M., Glorieux, C., Stockis, J., Sid, B., Sandoval, J. M., Felipe, K. B., Kviecinski, M. R., Verrax, J., & Calderón, P. B. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.380 · Cited by 75
Wang, J., Zhang, M., Zhang, L., Cai, H., Zhou, S., Zhang, J., & Wang, Y. (2010) · Journal of Surgical Research · doi:10.1016/j.jss.2010.05.058 · Cited by 75
Shen, H., Yang, Y. P., Xia, S., Rao, B., Zhang, J., & Wang, J. (2013) · Diseases of the Esophagus · doi:10.1111/dote.12124 · Cited by 73
Martínez, V. D., Vucic, E. A., Thu, K. L., Pikor, L. A., Lam, S. C., & Lam, W. L. (2014) · Head & Neck · doi:10.1002/hed.23663 · Cited by 72
Becks, L., Prince, M., Burson, H. C., Christophe, C., Broadway, M., Itoh, K., Yamamoto, M. P., Mathis, J. M., Orchard, E. A., Shi, R., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-540 · Cited by 72
Chao, C., Lii, C., Hsu, Y., Lu, C., Liu, K., Li, C., & Chen, H. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt131 · Cited by 72
Lu, D., Yeh, W., Huang, S.-M., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos262 · Cited by 72
E-cadherin inhibits nuclear accumulation of Nrf2: implications for chemoresistance of cancer cells
Kim, W., Kim, Y. W., Cho, I. J., Lee, C. H., & Kim, S. G. (2012) · Journal of Cell Science · doi:10.1242/jcs.095422 · Cited by 72
Nakamura, H., Liao, L., Hitaka, Y., Tsukigawa, K., Šubr, V., Fang, J. Q., Ulbrich, K., & Maeda, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.11.017 · Cited by 67
Mahaffey, C. M., Zhang, H., Rinna, A., Holland, W. S., Mack, P. C., & Forman, H. J. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.03.023 · Cited by 67
Lin, C.-C., Chiang, L.-L., Lin, C., Shih, C.-H., Liao, Y., Hsu, M., & Chen, B.-C. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.01.025 · Cited by 67
Banerjee, P., Basu, A., Datta, D. B., Gasser, M., Waaga-Gasser, A. M., & Pal, S. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.248401 · Cited by 66
Ryter, S. W., Xi, S., Hartsfield, C. L., & Choi, A. M. K. (2002) · Antioxidants and Redox Signaling · doi:10.1089/15230860260220085 · Cited by 64
Rushworth, S. A., Bowles, K. M., Raninga, P. V., & MacEwan, D. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3407 · Cited by 64
Martínez, V. D., Vucic, E. A., Pikor, L. A., Thu, K. L., Hubaux, R., & Lam, W. L. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-124 · Cited by 62
Nrf2, the master redox switch: The Achilles' heel of ovarian cancer?
van der Wijst, M. G. P., Brown, R. E., & Rots, M. G. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.09.004 · Cited by 55
HO-1 up-regulation: A key point in high-risk neuroblastoma resistance to bortezomib
Furfaro, A. L., Piras, S., Passalacqua, M., Domenicotti, C., Parodi, A., Fenoglio, D., Pronzato, M. A., Marinari, U. M., Moretta, L., Traverso, N., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.12.008 · Cited by 54
Self-citationJózkowicz, A., & Dulak, J. (2003) · Acta Biochimica Polonica · doi:10.18388/abp.2003_3715 · Cited by 53
Zhang, T., Kimura, Y., Jiang, S., Harada, K., Yamashita, Y., & Ashida, H. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.05.023 · Cited by 47
Bortezomib induces heme oxygenase-1 expression in multiple myeloma
Barrera, L. N., Rushworth, S. A., Bowles, K. M., & MacEwan, D. J. (2012) · Cell Cycle · doi:10.4161/cc.20343 · Cited by 45
Nemmiche, S., Chabane-Sari, D., Kadri, M., & Guiraud, P. (2012) · Toxicology · doi:10.1016/j.tox.2012.05.003 · Cited by 44
Ma, D., Fang, Q., Wang, P., Gao, R., Wu, W., Lu, T., Cao, L., Hu, X., & Wang, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.626960 · Cited by 43
Gan, F.-F., Ling, H. Y., Ang, X., Reddy, S. A., Lee, S. S.-H., Yang, H., Tan, S.-H., Hayes, J. D., Chui, W., & Chew, E. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.07.011 · Cited by 43
Cheng, P., Lee, Y., Shih, N., Chen, Y., & Yen, M. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.11.024 · Cited by 42
Furfaro, A. L., Macay, J. R. Z., Marengo, B., Nitti, M., Parodi, A., Fenoglio, D., Marinari, U. M., Pronzato, M. A., Domenicotti, C., & Traverso, N. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.11.007 · Cited by 42
Self-citationLee, S., Yang, S., Tsai, C., Chou, M., Chou, M., & Chang, Y. (2008) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(08)60100-x · Cited by 41
Thimmulappa, R. K., Rangasamy, T., Alam, J., & Biswal, S. S. (2008) · Medicinal Chemistry · doi:10.2174/157340608785700199 · Cited by 39
Fang, J. Q., Greish, K. F., Qin, H., Liao, L., Nakamura, H., Takeya, M., & Maeda, H. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.04.016 · Cited by 36
Martínez, V. D., Vucic, E. A., Thu, K. L., Pikor, L. A., Hubaux, R., & Lam, W. L. (2014) · BioMed Research International · doi:10.1155/2014/159459 · Cited by 36
The influence of iron homoeostasis on macrophage function
Ward, R. J., Wilmet, S., Legssyer, R., & Crichton, R. R. (2002) · Biochemical Society Transactions · doi:10.1042/bst0300762 · Cited by 35
Clinical Significance of Heme Oxygenase-1 Expression in Non-Muscle-Invasive Bladder Cancer
Miyake, M., Fujimoto, K., Anai, S., Ohnishi, S., Nakai, Y., Inoue, T., Matsumura, Y., Tomioka, A., Ikeda, T., Tanaka, N., et al. (2010) · Urologia Internationalis · doi:10.1159/000317785 · Cited by 34
Differential Nrf2 expression between glioma stem cells and non-stem-like cells in glioblastoma
Zhu, J., Wang, H., Ji, X., Zhu, L., Sun, Q., Cong, Z., Zhou, Y., Liu, H., & Zhou, M. (2013) · Oncology Letters · doi:10.3892/ol.2013.1760 · Cited by 33
Imine Resveratrol Analogues: Molecular Design, Nrf2 Activation and SAR Analysis
Li, C., Xu, X., Wang, X. J., & Pan, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101455 · Cited by 30
dos Santos, D. M., Santos, M. M. M., Moreira, R., Solá, S., & Rodrigues, C. M. P. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8353-y · Cited by 25
Zhang, W., Qiao, T., & Zha, L. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0939 · Cited by 23
Bancos, S., Baglole, C. J., Rahman, I., & Phipps, R. P. (2009) · Cellular Immunology · doi:10.1016/j.cellimm.2009.12.003 · Cited by 22
ZnPPIX inhibits peritoneal metastasis of gastric cancer via its antiangiogenic activity
Shang, F., Hui, L., An, X., et al. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.03.005 · Cited by 20
Discovery of oxime-bearing naphthalene derivatives as a novel structural type of Nrf2 activators
Chang, K., Liang, F.-P., Chen, I., Yang, S., Juang, S., Wang, T., Chen, Y., & Tzeng, C. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.03.046 · Cited by 10
Cited by
Modulating ROS to overcome multidrug resistance in cancer
Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.11.001 · Cited by 661
Nrf2 and Ferroptosis: A New Research Direction for Neurodegenerative Diseases
Song, X., & Long, D. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00267 · Cited by 577
Heme oxygenase-1 mediates BAY 11-7085 induced ferroptosis
Chang, L.-C., Chiang, S.-K., Chen, S.-E., Yu, Y.-L., Chou, R.-H., & Chang, W.-C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.12.025 · Cited by 521
Tagitinin C induces ferroptosis through PERK-Nrf2-HO-1 signaling pathway in colorectal cancer cells
Wei, R., Zhao, Y., Wang, J., Yang, X., Li, S., Wang, Y., Yang, X., Fei, J., Hao, X., Zhao, Y., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59404 · Cited by 434
Lou, J.-S., Zhao, L.-P., Huang, Z.-H., Chen, X.-Y., Xu, J.-T., TAI, W. C.-S., Tsim, K. W. K., Chen, Y.-T., & Xie, T. (2021) · Phytomedicine · doi:10.1016/j.phymed.2020.153370 · Cited by 346
Metadata
- Authors
- Furfaro, A. L., Traverso, N., Domenicotti, C., Piras, S., Moretta, L., Marinari, U. M., Pronzato, M. A., & Nitti, M.
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2015-11-30
- Volume
- 2016
- Issue
- 1
- Pages
- 1958174-1958174
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- OpenAlex
- W1920914663
- Cited by
- 295
- References
- 193
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.